JM Modern HikaShop - шаблон joomla Видео
(06-1) 619-8321

Cell3™ Target: Tumor Exome

Tumor Exome
Tumor Exome 2
Tumor exome sequencing
Whole exome capture with extensive clinically relevant content for comprehensive primary tumor sequencing.


Tumor relevant content


Whole exome capture designed specifically for cancer research covering key intronic regions like promoters, translocations and fusions and CNVs.

Range of sample types


Our tumor exome supports a broad range of sample types, including formalin-fixed, paraffin-embedded (FFPE) DNA, FF, gDNA and cell-free DNA (cfDNA).

Optimised performance


Delivering excellent uniformity of coverage, Cell3™ Target Tumor Exome reduces sequencing costs and improves sample throughput.



Designed to be flexible, Cell3™ Target Tumor Exome allows you to add extra content to cover targets specific to your project.

Primary tumor sequencing

By focusing on the coding regions of the genome, whole exome sequencing offers a cost-effective solution for primary tumour profiling when compared to whole genome sequencing. It allows for deeper sequencing enabling more sensitive mutation detection and improved tumor mutation burden (TMB) calling versus smaller panels.

However, many mutation types that are known to be important in cancer, for example tumor promoters like TERT, translocations and fusions or CNVs, are not covered by standard exome enrichments.  At Nonacus, we believe a different type of exome is required for cancer research.

Tumor relevant content for cancer research

The Nonacus Cell3™ Target Tumor Exome is based on our standard Whole Exome product enhanced with baits from our Pan-Cancer panel.  It includes enhanced coverage of the most clinically relevant genes from NCCN/FDA cancer treatment guidelines, 116 cancer driver genes and 345 genes in vital cancer signalling pathways. The design, whilst exon focused, covers key intronic and promoter regions like the TERT promoter and translocations and fusions. It also contains genome-wide CNV probes to support robust copy number calling. At 37.3Mb, it is a comprehensive panel that allows you to accurately identify and profile novel and known variants associated with cancer.

gene list for pan cancer panelFormalin fixed paraffin embedded (FFPE) block

Reliable sequencing for primary, metastatic or liquid biopsies

We know that you may want to use the same exome product on multiple sample types – especially when, for example, carrying out tumour/normal comparisons. The Cell3™ Target Tumor Exome kit has been developed for and validated on broad range of sample types, including formalin-fixed, paraffin-embedded (FFPE), fresh frozen, genomic and cell free DNA.

Low input FFPE and cfDNA sequencing.

Using from as little as 1 ng of genomic or cfDNA, with optimised protocols for FFPE our tumor exome unlocks the door for many oncology applications

Detect low frequency variants in primary tumors

The Cell3™ Target library preparation behind our tumor exome enrichment incorporates error suppression technology. This includes unique molecular indexes (UMIs) and unique dual indexes (UDIs), to remove both PCR and sequencing errors and index hopping events.

Diagram demonstrating Using UMI’s to identify and quantify individual DNA molecules during library preparation increases sensitivity

Figure 1. Using UMI’s to identify and quantify individual DNA molecules during library preparation increases sensitivity


Optimised sequencing performance

The baits used in Cell3™ Target Tumor Exome are designed to deliver excellent uniformity of coverage.  By improving uniformity of coverage and reducing the number of low coverage exons, our tumor exome enrichment optimises sequencing efficiency  and sample capacity per sequencing run.

Customise content for cancer profiling

Designed to be flexible, Cell3™ Target Tumor Exome allows you to add extra content specific to your project. Whether this is additional content or increased coverage of existing content, our Probe Design Tool makes this a simple and easy process to implement. And our rapid production turnaround means you will receive a fully NGS-validated custom exome within 4 weeks.

  • Additional content with high enrichment uniformity
  • Increased coverage of specific genes covered by Cell3™ Target Tumor Exome
  • Optimization of spike-in ratio

Screenshot of Nonacus Probe design tool homepage


blue down arrowForgalmazott termékeink gyártói - keressen gyártó szerint a logóra kattintva